ReviewFree neuropathology2026
Neurooncology: 2026 update.
Review in Free neuropathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present collection of studies highlights major conceptual and translational advances in contemporary neurooncology related to the field of neuropathology. Central themes include the increasing recognition of neuron-tumor interactions, immune microenvironment remodeling, vascular heterogeneity, and epigenetic plasticity as key drivers of brain tumor progression and therapeutic resistance. Glioblastoma emerges as a highly dynamic and synaptically integrated disease entity, while melanoma brain metastases demonstrate profound microglial reprogramming with direct implications for immunotherapy. Novel molecular and spatial profiling approaches further reveal distinct vascular and immune landscapes across gliomas and brain metastases as well as lineage-dependent developmental programs in medulloblastoma. In parallel, rapid advances in artificial intelligence, nanopore sequencing, and real-time molecular diagnostics are reshaping neuropathological workflows and intraoperative decision-making. Proteomic and multi-omics analyses additionally uncover clinically relevant immune-hot glioma subtypes associated with adverse prognosis and spatial immune remodeling. Together, these studies underscore the increasing convergence of molecular neurobiology, immunology, epigenetics, and computational pathology in modern neurooncology and highlight emerging opportunities for precision diagnostics and targeted therapeutic intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.